Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia

Stanley N. Caroff, Vicki G. Davis, Del D. Miller, Sonia M. Davis, Robert A. Rosenheck, Joseph Patrick McEvoy, E. Cabrina Campbell, Bruce L. Saltz, Silvana Riggio, Miranda H. Chakos, Marvin S. Swartz, Richard S.E. Keefe, T. Scott Stroup, Jeffrey A. Lieberman

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objective: We compared the response to antipsychotic treatment between patients with and without tardive dyskinesia (TD) and examined the course of TD. Method: This analysis compared 200 patients with DSM-IV-defined schizophrenia and TD and 997 patients without TD, all of whom were randomly assigned to receive one of 4 second-generation antipsychotics. The primary clinical outcome measure was time to allcause treatment discontinuation, and the primary measure for evaluating the course of TD was change from baseline in Abnormal Involuntary Movement Scale (AIMS) score. Kaplan-Meier survival analysis and Cox proportional hazards regression models were used to compare treatment discontinuation between groups. Changes in Positive and Negative Syndrome Scale (PANSS) and neurocognitive scores were compared using mixed models and analysis of variance. Treatment differences between drugs in AIMS scores and all-cause discontinuation were examined for those with TD at baseline. Percentages of patients meeting criteria for TD postbase-line or showing changes in AIMS scores were evaluated with χ2 tests. Data were collected from January 2001 to December 2004. Results: Time to treatment discontinuation for any cause was not significantly different between the TD and non-TD groups (χ21 = 0.11, P = .743). Changes in PANSS scores were not significantly different (F1,974 = 0.82, P = .366), but patients with TD showed less improvement in neurocognitive scores (F1,359 = 6.53, P = .011). Among patients with TD, there were no significant differences between drugs in the decline in AIMS scores (F3,151 = 0.32, P = .811); 55% met criteria for TD at 2 consecutive visits postbaseline, 76% met criteria for TD at some or all postbaseline visits, 24% did not meet criteria for TD at any subsequent visit, 32% showed a ≥ 50% decrease in AIMS score, and 7% showed a ≥ 50% increase in AIMS score. Conclusions: Schizophrenia patients with and without TD were similar in time to discontinuation of treatment for any cause and improvement in psychopathology, but differed in neurocognitive response. There were no significant differences between treatments in the course of TD, with most patients showing either persistence of or fluctuation in observable symptoms.

Original languageEnglish (US)
Pages (from-to)295-303
Number of pages9
JournalJournal of Clinical Psychiatry
Volume72
Issue number3
DOIs
StatePublished - Mar 1 2011
Externally publishedYes

Fingerprint

Schizophrenia
Tardive Dyskinesia
Therapeutics
Antipsychotic Agents
Dyskinesias
Kaplan-Meier Estimate
Survival Analysis
Psychopathology
Proportional Hazards Models
Diagnostic and Statistical Manual of Mental Disorders
Pharmaceutical Preparations
Abnormal Involuntary Movement Scale
Analysis of Variance
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Caroff, S. N., Davis, V. G., Miller, D. D., Davis, S. M., Rosenheck, R. A., McEvoy, J. P., ... Lieberman, J. A. (2011). Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. Journal of Clinical Psychiatry, 72(3), 295-303. https://doi.org/10.4088/JCP.09m05793yel

Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. / Caroff, Stanley N.; Davis, Vicki G.; Miller, Del D.; Davis, Sonia M.; Rosenheck, Robert A.; McEvoy, Joseph Patrick; Campbell, E. Cabrina; Saltz, Bruce L.; Riggio, Silvana; Chakos, Miranda H.; Swartz, Marvin S.; Keefe, Richard S.E.; Stroup, T. Scott; Lieberman, Jeffrey A.

In: Journal of Clinical Psychiatry, Vol. 72, No. 3, 01.03.2011, p. 295-303.

Research output: Contribution to journalArticle

Caroff, SN, Davis, VG, Miller, DD, Davis, SM, Rosenheck, RA, McEvoy, JP, Campbell, EC, Saltz, BL, Riggio, S, Chakos, MH, Swartz, MS, Keefe, RSE, Stroup, TS & Lieberman, JA 2011, 'Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia', Journal of Clinical Psychiatry, vol. 72, no. 3, pp. 295-303. https://doi.org/10.4088/JCP.09m05793yel
Caroff, Stanley N. ; Davis, Vicki G. ; Miller, Del D. ; Davis, Sonia M. ; Rosenheck, Robert A. ; McEvoy, Joseph Patrick ; Campbell, E. Cabrina ; Saltz, Bruce L. ; Riggio, Silvana ; Chakos, Miranda H. ; Swartz, Marvin S. ; Keefe, Richard S.E. ; Stroup, T. Scott ; Lieberman, Jeffrey A. / Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. In: Journal of Clinical Psychiatry. 2011 ; Vol. 72, No. 3. pp. 295-303.
@article{8e6a0058bc84493c85b774bba0d77496,
title = "Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia",
abstract = "Objective: We compared the response to antipsychotic treatment between patients with and without tardive dyskinesia (TD) and examined the course of TD. Method: This analysis compared 200 patients with DSM-IV-defined schizophrenia and TD and 997 patients without TD, all of whom were randomly assigned to receive one of 4 second-generation antipsychotics. The primary clinical outcome measure was time to allcause treatment discontinuation, and the primary measure for evaluating the course of TD was change from baseline in Abnormal Involuntary Movement Scale (AIMS) score. Kaplan-Meier survival analysis and Cox proportional hazards regression models were used to compare treatment discontinuation between groups. Changes in Positive and Negative Syndrome Scale (PANSS) and neurocognitive scores were compared using mixed models and analysis of variance. Treatment differences between drugs in AIMS scores and all-cause discontinuation were examined for those with TD at baseline. Percentages of patients meeting criteria for TD postbase-line or showing changes in AIMS scores were evaluated with χ2 tests. Data were collected from January 2001 to December 2004. Results: Time to treatment discontinuation for any cause was not significantly different between the TD and non-TD groups (χ21 = 0.11, P = .743). Changes in PANSS scores were not significantly different (F1,974 = 0.82, P = .366), but patients with TD showed less improvement in neurocognitive scores (F1,359 = 6.53, P = .011). Among patients with TD, there were no significant differences between drugs in the decline in AIMS scores (F3,151 = 0.32, P = .811); 55{\%} met criteria for TD at 2 consecutive visits postbaseline, 76{\%} met criteria for TD at some or all postbaseline visits, 24{\%} did not meet criteria for TD at any subsequent visit, 32{\%} showed a ≥ 50{\%} decrease in AIMS score, and 7{\%} showed a ≥ 50{\%} increase in AIMS score. Conclusions: Schizophrenia patients with and without TD were similar in time to discontinuation of treatment for any cause and improvement in psychopathology, but differed in neurocognitive response. There were no significant differences between treatments in the course of TD, with most patients showing either persistence of or fluctuation in observable symptoms.",
author = "Caroff, {Stanley N.} and Davis, {Vicki G.} and Miller, {Del D.} and Davis, {Sonia M.} and Rosenheck, {Robert A.} and McEvoy, {Joseph Patrick} and Campbell, {E. Cabrina} and Saltz, {Bruce L.} and Silvana Riggio and Chakos, {Miranda H.} and Swartz, {Marvin S.} and Keefe, {Richard S.E.} and Stroup, {T. Scott} and Lieberman, {Jeffrey A.}",
year = "2011",
month = "3",
day = "1",
doi = "10.4088/JCP.09m05793yel",
language = "English (US)",
volume = "72",
pages = "295--303",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "3",

}

TY - JOUR

T1 - Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia

AU - Caroff, Stanley N.

AU - Davis, Vicki G.

AU - Miller, Del D.

AU - Davis, Sonia M.

AU - Rosenheck, Robert A.

AU - McEvoy, Joseph Patrick

AU - Campbell, E. Cabrina

AU - Saltz, Bruce L.

AU - Riggio, Silvana

AU - Chakos, Miranda H.

AU - Swartz, Marvin S.

AU - Keefe, Richard S.E.

AU - Stroup, T. Scott

AU - Lieberman, Jeffrey A.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Objective: We compared the response to antipsychotic treatment between patients with and without tardive dyskinesia (TD) and examined the course of TD. Method: This analysis compared 200 patients with DSM-IV-defined schizophrenia and TD and 997 patients without TD, all of whom were randomly assigned to receive one of 4 second-generation antipsychotics. The primary clinical outcome measure was time to allcause treatment discontinuation, and the primary measure for evaluating the course of TD was change from baseline in Abnormal Involuntary Movement Scale (AIMS) score. Kaplan-Meier survival analysis and Cox proportional hazards regression models were used to compare treatment discontinuation between groups. Changes in Positive and Negative Syndrome Scale (PANSS) and neurocognitive scores were compared using mixed models and analysis of variance. Treatment differences between drugs in AIMS scores and all-cause discontinuation were examined for those with TD at baseline. Percentages of patients meeting criteria for TD postbase-line or showing changes in AIMS scores were evaluated with χ2 tests. Data were collected from January 2001 to December 2004. Results: Time to treatment discontinuation for any cause was not significantly different between the TD and non-TD groups (χ21 = 0.11, P = .743). Changes in PANSS scores were not significantly different (F1,974 = 0.82, P = .366), but patients with TD showed less improvement in neurocognitive scores (F1,359 = 6.53, P = .011). Among patients with TD, there were no significant differences between drugs in the decline in AIMS scores (F3,151 = 0.32, P = .811); 55% met criteria for TD at 2 consecutive visits postbaseline, 76% met criteria for TD at some or all postbaseline visits, 24% did not meet criteria for TD at any subsequent visit, 32% showed a ≥ 50% decrease in AIMS score, and 7% showed a ≥ 50% increase in AIMS score. Conclusions: Schizophrenia patients with and without TD were similar in time to discontinuation of treatment for any cause and improvement in psychopathology, but differed in neurocognitive response. There were no significant differences between treatments in the course of TD, with most patients showing either persistence of or fluctuation in observable symptoms.

AB - Objective: We compared the response to antipsychotic treatment between patients with and without tardive dyskinesia (TD) and examined the course of TD. Method: This analysis compared 200 patients with DSM-IV-defined schizophrenia and TD and 997 patients without TD, all of whom were randomly assigned to receive one of 4 second-generation antipsychotics. The primary clinical outcome measure was time to allcause treatment discontinuation, and the primary measure for evaluating the course of TD was change from baseline in Abnormal Involuntary Movement Scale (AIMS) score. Kaplan-Meier survival analysis and Cox proportional hazards regression models were used to compare treatment discontinuation between groups. Changes in Positive and Negative Syndrome Scale (PANSS) and neurocognitive scores were compared using mixed models and analysis of variance. Treatment differences between drugs in AIMS scores and all-cause discontinuation were examined for those with TD at baseline. Percentages of patients meeting criteria for TD postbase-line or showing changes in AIMS scores were evaluated with χ2 tests. Data were collected from January 2001 to December 2004. Results: Time to treatment discontinuation for any cause was not significantly different between the TD and non-TD groups (χ21 = 0.11, P = .743). Changes in PANSS scores were not significantly different (F1,974 = 0.82, P = .366), but patients with TD showed less improvement in neurocognitive scores (F1,359 = 6.53, P = .011). Among patients with TD, there were no significant differences between drugs in the decline in AIMS scores (F3,151 = 0.32, P = .811); 55% met criteria for TD at 2 consecutive visits postbaseline, 76% met criteria for TD at some or all postbaseline visits, 24% did not meet criteria for TD at any subsequent visit, 32% showed a ≥ 50% decrease in AIMS score, and 7% showed a ≥ 50% increase in AIMS score. Conclusions: Schizophrenia patients with and without TD were similar in time to discontinuation of treatment for any cause and improvement in psychopathology, but differed in neurocognitive response. There were no significant differences between treatments in the course of TD, with most patients showing either persistence of or fluctuation in observable symptoms.

UR - http://www.scopus.com/inward/record.url?scp=79953047492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953047492&partnerID=8YFLogxK

U2 - 10.4088/JCP.09m05793yel

DO - 10.4088/JCP.09m05793yel

M3 - Article

C2 - 20816031

AN - SCOPUS:79953047492

VL - 72

SP - 295

EP - 303

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 3

ER -